



Description générale

| | |
|----------------------------|---|
| INN | Doxorubicin |
| Codes ATC | L01DB01 |
| Type de médicament | Chemical agent |
| Historique des statuts LME | Ajouté pour la première fois en 2023 (TRS 1049) pour Kaposi sarcoma of unspecified primary site |
| Wikipédia | Doxorubicin (as pegylated liposomal) ↗ |
| DrugBank | Doxorubicin (as pegylated liposomal) (Doxorubicin) ↗ |

Recommandations

Section Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

